Literature DB >> 22261766

Hepatocellular carcinoma presenting at contrast-enhanced multi-detector-row computed tomography or gadolinium-enhanced magnetic resonance imaging as a small (≤2 cm), indeterminate nodule: growth rate and optimal interval time for imaging follow-up.

Alessandro Furlan1, Daniele Marin, Francesco Agnello, Michele Di Martino, Vito Di Marco, Roberto Lagalla, Carlo Catalano, Giuseppe Brancatelli.   

Abstract

OBJECTIVE: The objective of the study was to measure growth rate and to determine the optimal interval time for imaging follow-up of hepatocellular carcinomas (HCCs) presenting at multi-detector-row computed tomography (MDCT) or magnetic resonance imaging (MRI) as small, indeterminate lesions.
METHODS: We included patients with cirrhosis with HCC initially presenting as indeterminate lesion of 2 cm or less at MDCT or MRI August 2005 to August 2009 and with available imaging follow-up. Measures of tumor growth included tumor volume doubling time (TVDT), tumor percentual diameter increase, and tumor percentual volume increase.
RESULTS: We examined 48 patients (mean age, 64 years) with 69 HCCs. At index examination, mean (SD) maximum transverse diameter and volume of lesions were 1.2 (SD, 0.3) cm and 0.6 (SD, 0.7) cm, respectively. Median TVDT was 210 days. Tumors with follow-up longer than 365 days had significant increase in tumor percentual diameter increase and tumor percentual volume increase.
CONCLUSIONS: Median TVDT of 210 days suggests extended follow-up of 6 months for small, indeterminate liver nodules detected at MDCT or MRI.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22261766     DOI: 10.1097/RCT.0b013e31823ed462

Source DB:  PubMed          Journal:  J Comput Assist Tomogr        ISSN: 0363-8715            Impact factor:   1.826


  10 in total

1.  Evaluating the validity of model for end-stage liver disease exception points for hepatocellular carcinoma patients with multiple nodules <2 cm.

Authors:  Mariya L Samoylova; Jennifer L Dodge; Neil Mehta; Francis Y Yao; John P Roberts
Journal:  Clin Transplant       Date:  2014-12-01       Impact factor: 2.863

2.  An indeterminate nodule in the cirrhotic liver discovered by surveillance imaging is a prelude to malignancy.

Authors:  Eliza W Beal; Scott Albert; Megan McNally; Lawrence A Shirley; James Hanje; Anthony J Michaels; Sylvester M Black; Mark Bloomston; Carl R Schmidt
Journal:  J Surg Oncol       Date:  2014-08-25       Impact factor: 3.454

3.  Dynamic changes in ultrasound characteristics of nodules in cirrhotic liver and their implications in surveillance for malignancy.

Authors:  Size Wu; Rong Tu; Guangqing Liu; Yusen Shi
Journal:  J Med Ultrason (2001)       Date:  2013-09-03       Impact factor: 1.314

4.  Focal lesions in cirrhotic liver: what else beyond hepatocellular carcinoma?

Authors:  Massimo Galia; Adele Taibbi; Daniele Marin; Alessandro Furlan; Marco Dioguardi Burgio; Francesco Agnello; Giuseppe Cabibbo; Bernard E Van Beers; Tommaso Vincenzo Bartolotta; Massimo Midiri; Roberto Lagalla; Giuseppe Brancatelli
Journal:  Diagn Interv Radiol       Date:  2014 May-Jun       Impact factor: 2.630

Review 5.  Joint Consensus Statement of the Indian National Association for Study of the Liver and Indian Radiological and Imaging Association for the Diagnosis and Imaging of Hepatocellular Carcinoma Incorporating Liver Imaging Reporting and Data System.

Authors:  Sonal Krishan; Radha K Dhiman; Navin Kalra; Raju Sharma; Sanjay S Baijal; Anil Arora; Ajay Gulati; Anu Eapan; Ashish Verma; Shyam Keshava; Amar Mukund; S Deva; Ravi Chaudhary; Karthick Ganesan; Sunil Taneja; Ujjwal Gorsi; Shivanand Gamanagatti; Kumble S Madhusudan; Pankaj Puri; Shallini Govil; Manav Wadhavan; Sanjiv Saigal; Ashish Kumar; Shallini Thapar; Ajay Duseja; Neeraj Saraf; Anubhav Khandelwal; Sumit Mukhopadyay; Ajay Gulati; Nitin Shetty; Nipun Verma
Journal:  J Clin Exp Hepatol       Date:  2019-08-06

Review 6.  Evidence Supporting LI-RADS Major Features for CT- and MR Imaging-based Diagnosis of Hepatocellular Carcinoma: A Systematic Review.

Authors:  An Tang; Mustafa R Bashir; Michael T Corwin; Irene Cruite; Christoph F Dietrich; Richard K G Do; Eric C Ehman; Kathryn J Fowler; Hero K Hussain; Reena C Jha; Adib R Karam; Adrija Mamidipalli; Robert M Marks; Donald G Mitchell; Tara A Morgan; Michael A Ohliger; Amol Shah; Kim-Nhien Vu; Claude B Sirlin
Journal:  Radiology       Date:  2017-11-21       Impact factor: 11.105

7.  Serological and histological indices of hepatocellular carcinoma and tumor volume doubling time.

Authors:  Naoki Shingaki; Hideyuki Tamai; Yoshiyuki Mori; Kosaku Moribata; Shotaro Enomoto; Hisanobu Deguchi; Kazuki Ueda; Izumi Inoue; Takao Maekita; Mikitaka Iguchi; Jun Kato; Masao Ichinose
Journal:  Mol Clin Oncol       Date:  2013-09-17

8.  Tailored algorithms for hepatocellular carcinoma surveillance: Is one-size-fits-all strategy outdated?

Authors:  Nicolas Goossens; C Billie Bian; Yujin Hoshida
Journal:  Curr Hepatol Rep       Date:  2017-02-01

9.  Hepatocellular carcinoma tumour volume doubling time: a systematic review and meta-analysis.

Authors:  Piyush Nathani; Purva Gopal; Nicole Rich; Adam Yopp; Takeshi Yokoo; Binu John; Jorge Marrero; Neehar Parikh; Amit G Singal
Journal:  Gut       Date:  2020-05-12       Impact factor: 23.059

Review 10.  Risk factors and prevention of hepatocellular carcinoma in the era of precision medicine.

Authors:  Naoto Fujiwara; Scott L Friedman; Nicolas Goossens; Yujin Hoshida
Journal:  J Hepatol       Date:  2017-10-06       Impact factor: 30.083

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.